(Q37171491)

18 August 2017

1 reference

title

The malonyl CoA axis as a potential target for treating ischaemic heart disease (English)

1 reference

18 August 2017

John R Ussher

1

1 reference

PubMed ID

18499682

18 August 2017

Gary D Lopaschuk

series ordinal

2

1 reference

18 August 2017

22 May 2008

1 reference

18 August 2017

Cardiovascular Research

1 reference

18 August 2017

79

1 reference

18 August 2017

2

1 reference

18 August 2017

259-268

1 reference

High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation

18 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Role of malonyl-CoA in heart disease and the hypothalamic control of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Myocardial substrate metabolism in the normal and failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Malonyl CoA control of fatty acid oxidation in the ischemic heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Cardiac fatty acid uptake and transport in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Assay of the concentration and 13C-isotopic enrichment of malonyl-coenzyme A by gas chromatography-mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

AMPK alterations in cardiac physiology and pathology: enemy or ally?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

MCD encodes peroxisomal and cytoplasmic forms of malonyl-CoA decarboxylase and is mutated in malonyl-CoA decarboxylase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Peroxisomal fatty acid oxidation is a substantial source of the acetyl moiety of malonyl-CoA in rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Effects of acidosis on ventricular muscle from adult and neonatal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Plasma fatty acid levels in infants and adults after myocardial ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Free fatty acids during acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMP-dependent protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Dual mechanisms regulating AMPK kinase action in the ischemic heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Stress signaling in the heart by AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Role of the alpha2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarct

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

A new case of malonyl coenzyme A decarboxylase deficiency presenting with cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Modification of left ventricular hypertrophy by chronic etomixir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Brain abnormalities in a case of malonyl-CoA decarboxylase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Cardiomyopathy and hypotonia in a 5-month-old infant with malonyl-coa decarboxylase deficiency: potential for preclinical diagnosis with expanded newborn screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

MLYCD mutation analysis: evidence for protein mistargeting as a cause of MLYCD deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

Activation of Malonyl-CoA Decarboxylase in Rat Skeletal Muscle by Contraction and the AMP-activated Protein Kinase Activator 5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN130

21 January 2018

Identifiers

DOI

10.1093/CVR/CVN130

1 reference

18 August 2017

1 reference

PubMed ID

18499682